News coverage about Accuray (NASDAQ:ARAY) has been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Accuray earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 46.9756386355476 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Accuray to Present at the 2018 RBC Capital Markets Global Healthcare Conference on February 22, 2018 (finance.yahoo.com)
- Zacks Investment Research Lowers Accuray (ARAY) to Hold (americanbankingnews.com)
- Accuray (ARAY) Upgraded at Zacks Investment Research (americanbankingnews.com)
- BidaskClub Lowers Accuray (ARAY) to Hold (americanbankingnews.com)
- Accuray Incorporated (ARAY) Expected to Post Quarterly Sales of $98.18 Million (americanbankingnews.com)
Several research firms have issued reports on ARAY. BidaskClub lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Zacks Investment Research lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Royal Bank of Canada set a $6.00 price target on shares of Accuray and gave the stock a “hold” rating in a research report on Wednesday, January 24th. JPMorgan Chase & Co. lowered shares of Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price target on the stock. in a research report on Wednesday, December 13th. Finally, Lake Street Capital initiated coverage on shares of Accuray in a research report on Thursday, November 30th. They set a “buy” rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $7.13.
Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. Accuray had a negative net margin of 6.09% and a negative return on equity of 44.66%. The firm had revenue of $100.33 million for the quarter, compared to analysts’ expectations of $90.31 million. During the same period in the previous year, the company posted ($0.11) EPS. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. equities analysts anticipate that Accuray will post -0.19 earnings per share for the current year.
In other Accuray news, CFO Kevin Waters sold 7,154 shares of Accuray stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $5.06, for a total transaction of $36,199.24. Following the transaction, the chief financial officer now directly owns 335,087 shares in the company, valued at approximately $1,695,540.22. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Joshua Levine sold 17,093 shares of Accuray stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.86, for a total transaction of $83,071.98. Following the transaction, the chief executive officer now owns 1,435,428 shares in the company, valued at $6,976,180.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,413 shares of company stock worth $129,798. Corporate insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Accuray (ARAY) Share Price” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://stocknewstimes.com/2018/02/17/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-accuray-aray-share-price.html.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.